Nutex Health Inc (NUTX)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ
Market Cap: $1.19B
Last updated: Nov 17, 2026 at 11:06 AM ET
Nutex Health Inc (NUTX) Stock Forecast
Analysts expect Nutex Health (NUTX) to earn $27.46 per share in the fiscal year ending Dec 31, 2026, on revenue of $869.99M. Of 6 analysts, 6 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 5 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 1.83, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 16.7% |
| Buy | 5 | 83.3% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 6
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 1.8% and revenue estimates rise 10.9%.
- Fiscal year ending Dec 31, 2026
- $27.46
- EPS consensus, revenue $869.99M
- Fiscal year ending Dec 31, 2027
- $27.95
- EPS consensus, revenue $964.79M
- Next report
- Mar 3, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $27.46 | $26.62 to $28.08 | 6 | $869.99M | $864.92M to $874.20M | 5 |
| Dec 31, 2027 | $27.95 | $24.05 to $31.09 | 6 | $964.79M | $946.33M to $996.10M | 6 |
Quarterly Estimates
The EPS consensus rises from $6.03 for the quarter ending Dec 31, 2026 to $7.09 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $6.03 | $5.57 to $6.56 | 7 | $231.16M | $215.66M to $243.39M | 7 |
| Mar 31, 2027 | $7.09 | $5.95 to $7.81 | 6 | $234.93M | $232.10M to $241.10M | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 12 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 5 | 0 |
| Fiscal year ending Dec 31, 2027 | 5 | 0 |
| Quarter ending Mar 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 2.0% from $28.03.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $27.46 | $27.37 | $27.79 | $27.79 | $28.03 | -2.0% |
| Fiscal year ending Dec 31, 2027 | $27.95 | $27.32 | $27.87 | $27.87 | $27.80 | +0.5% |
| Quarter ending Mar 31, 2027 | $7.09 | $7.05 | $7.33 | $7.33 | $7.44 | -4.7% |
Frequently Asked Questions About NUTX
What is the NUTX stock forecast?
Consensus analyst estimates put Nutex Health's EPS at $27.46 for the fiscal year ending Dec 31, 2026, on revenue of $869.99M. The consensus rating from 6 analysts is Buy.
How do analysts rate NUTX stock?
Of 6 analysts covering Nutex Health, 1 rates it Strong Buy, 5 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from NUTX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $27.46, with estimates from $26.62 to $28.08 from 6 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $27.95, with estimates from $24.05 to $31.09 from 6 analysts.
What revenue do analysts expect from Nutex Health next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $869.99M, with estimates from $864.92M to $874.20M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $964.79M, with estimates from $946.33M to $996.10M.
How many analysts cover NUTX?
6 analysts rate Nutex Health stock, and 6 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
NUTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors